Enterobacteria constitute a family of Gram negative bacilli of the gastrointestinal flora. These micro-organisms are frequently responsible for nosocomial or community-acquired infections, for which treatment is essentially based on the use of beta-lactam antibiotics. This class of antibiotics comprises penicillins, cephalosporins, monobactams and carbapenems. Carbapenems have the advantage of possessing a broad antibacterial spectrum and the capacity to resist the hydrolytic action of a large number of beta-lactamases, widespread inactivating enzymes. However, new enzymes, called carbapenemases, able to confer resistance to carbapenems either alone or in combination with additional resistance mechanisms such as loss of membrane permeability or overexpression of efflux systems, are currently emerging all over the world. Carbapenemases represent a major public health problem because of the risk of therapeutic impasse and their high epidemic potential.
Study Type
OBSERVATIONAL
Enrollment
287
CH Abbeville
Abbeville, France
CHU Amiens
Amiens, France
CH Beauvais
Beauvais, France
CHU Caen
Caen, France
CHU Compiegne
Compiègne, France
CHRU Lille
Lille, France
prevalence of clinical strains of Enterobacteria
Time frame: 1 year
characterization of the mechanisms responsible for carbapenems resistance
Time frame: 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.